10% Free customization
This report comes with 10% free customization, enabling you to add data that meets your specific business needs.
1 of 5
“High Demand for Combination Therapy and Pressure Point Therapy Likely to Boost CINV & PONV Market”
FEATURED COMPANIES
- Eisai Co., Ltd.
- Helsinn Holding S.A.
- Merck & Co., Inc.
- MORE
Chemotherapy-Induced Nausea and Vomiting (CINV) is one of the devastating side effects for patients undergoing cancer treatment. It is caused when various types of poisonous substances such as chemotherapeutic agents enter in the human body and alert the digestive system during chemotherapy. Besides chemotherapy, there are various types of factors that puts a patient high risk for CINV including female sex, history of alcohol use, CINV & motion sickness and anxiety or depression.
Postoperative Nausea and Vomiting (PONV) is referred to as a situation in which an inpatient experiences nausea and/or vomiting within the first 24-48 hours after undergoing surgery with general anesthesia. The incidence of PONV is 30% in the all post-surgical patients and 80% in high-risk patients. PONV is caused due to various factors including anesthetic choices, patient and surgery-specific. Treatment of PONV is done through prophylaxis and rescue treatment.
The U.S. emerged as a major region for the CINV & PONV market due to rising healthcare concerns and expenditure of the U.S. populace and growing CINV & PONV patient population.
The global CINV & PONV market is expected to grow with increasing cancer incidence, growing female population, increasing pharmaceutical R&D spending, growing healthcare expenditure and accelerating economic growth. Key trends and developments of this market includes progressing drugs under pipeline, high demand for combination therapy and increasing preference for pressure point therapy. However, there are some factors which can hinder growth of the market including entry of generics, stringent regulations and treatment cost.
The report “Global Chemotherapy-Induced Nausea and Vomiting (CINV) & Postoperative Nausea and Vomiting (PONV) Market: Industry Analysis & Outlook (2018-2022)” provides an extensive research and detailed analysis of the present market along with future outlook. The report discusses the major growth drivers, key tends & developments and challenges of the market, covering the U.S., Europe along with the global market. The report profiles the key players of the market including Merck & Co., Inc., Kirin Holding Company Limited (ProStrakan), Eisai Co., Ltd. and Helsinn Holding S.A.
Please note: 10% free customization equates to up to 3 hours of analyst time.
Postoperative Nausea and Vomiting (PONV) is referred to as a situation in which an inpatient experiences nausea and/or vomiting within the first 24-48 hours after undergoing surgery with general anesthesia. The incidence of PONV is 30% in the all post-surgical patients and 80% in high-risk patients. PONV is caused due to various factors including anesthetic choices, patient and surgery-specific. Treatment of PONV is done through prophylaxis and rescue treatment.
The U.S. emerged as a major region for the CINV & PONV market due to rising healthcare concerns and expenditure of the U.S. populace and growing CINV & PONV patient population.
The global CINV & PONV market is expected to grow with increasing cancer incidence, growing female population, increasing pharmaceutical R&D spending, growing healthcare expenditure and accelerating economic growth. Key trends and developments of this market includes progressing drugs under pipeline, high demand for combination therapy and increasing preference for pressure point therapy. However, there are some factors which can hinder growth of the market including entry of generics, stringent regulations and treatment cost.
The report “Global Chemotherapy-Induced Nausea and Vomiting (CINV) & Postoperative Nausea and Vomiting (PONV) Market: Industry Analysis & Outlook (2018-2022)” provides an extensive research and detailed analysis of the present market along with future outlook. The report discusses the major growth drivers, key tends & developments and challenges of the market, covering the U.S., Europe along with the global market. The report profiles the key players of the market including Merck & Co., Inc., Kirin Holding Company Limited (ProStrakan), Eisai Co., Ltd. and Helsinn Holding S.A.
Please note: 10% free customization equates to up to 3 hours of analyst time.
Note: Product cover images may vary from those shown
2 of 5
FEATURED COMPANIES
- Eisai Co., Ltd.
- Helsinn Holding S.A.
- Merck & Co., Inc.
- MORE
1. CINV & PONV Overview
1.1 CINV
1.2 PONV
2. Global CINV & PONV Market
2.1 Global CINV Market Forecast by Value
2.2 Global PONV Market Forecast by Value
3. Regional CINV & PONV Market
3.1 The U.S. CINV & PONV Market Forecast by Value
3.2 The U.S. CINV & PONV Drugs Revenue by Categories
3.3 The U.S. CINV & PONV Drugs Revenue
3.3.1 The U.S. Aloxi Drug Revenue
3.3.2 The U.S. Aloxi Drug Revenue Forecast
3.3.3 The U.S. Emend Drug Revenue Forecast
3.4 The U.S. CINV Drugs Revenue
3.4.1 The U.S. Sustol Drug Revenue Forecast
3.4.2 The U.S. Cinvanti Drug Revenue Forecast
3.4.3 The U.S. Varubi Oral Drug Revenue Forecast
3.4.4 The U.S. Varubi IV Drug Revenue Forecast
3.5 The U.S. PONV Patient Population Forecast
3.6 The U.S. PONV Drugs Revenue
3.6.1 The U.S. Baremsis Drug Revenue Forecast
3.7 Europe CINV Drugs Revenue
3.7.1 Europe Varuby Oral Drug Revenue Forecast
3.7.2 Europe Varuby IV Drug Revenue Forecast
4. Market Dynamics
4.1 Growth Drivers
4.1.1 Increasing Cancer Incidence
4.1.2 Growing Female Population
4.1.3 Increasing Pharmaceutical R&D Spending
4.1.4 Growing Healthcare Expenditure
4.1.5 Accelerating Economic Growth
4.2 Key Trends and Developments
4.2.1 Progressing Drugs under Pipeline
4.2.2 High Demand for Combination Therapy
4.2.3 Increasing Preference for Pressure Point Therapy
4.3 Challenges
4.3.1 Entry of Generics
4.3.2 Stringent Regulations
4.3.3 Treatment Cost
5. Competitive Landscape
5.1 Global Market
5.1.1 Revenue Comparison of Key Players
5.1.2 CINV & PONV Treatment Cost Comparison by Company
5.2 The U.S.
5.2.1 The U.S. CINV and PONV Market Share by Company
6. Company Profiles
6.1 Merck & Co., Inc.
6.1.1 Business Overview
6.1.2 Financial Overview
6.1.3 Business Strategies
6.2 Eisai Co., Ltd.
6.2.1 Business Overview
6.2.2 Financial Overview
6.2.3 Business Strategies
6.3 Kirin Holding Company, Limited (ProStrakan)
6.3.1 Business Overview
6.3.2 Financial Overview
6.3.3 Business Strategies
6.4 Helsinn Holding S.A.
6.4.1 Business Overview
6.4.2 Financial Overview
6.4.3 Business Strategies
List of Figures
1.1 CINV
1.2 PONV
2. Global CINV & PONV Market
2.1 Global CINV Market Forecast by Value
2.2 Global PONV Market Forecast by Value
3. Regional CINV & PONV Market
3.1 The U.S. CINV & PONV Market Forecast by Value
3.2 The U.S. CINV & PONV Drugs Revenue by Categories
3.3 The U.S. CINV & PONV Drugs Revenue
3.3.1 The U.S. Aloxi Drug Revenue
3.3.2 The U.S. Aloxi Drug Revenue Forecast
3.3.3 The U.S. Emend Drug Revenue Forecast
3.4 The U.S. CINV Drugs Revenue
3.4.1 The U.S. Sustol Drug Revenue Forecast
3.4.2 The U.S. Cinvanti Drug Revenue Forecast
3.4.3 The U.S. Varubi Oral Drug Revenue Forecast
3.4.4 The U.S. Varubi IV Drug Revenue Forecast
3.5 The U.S. PONV Patient Population Forecast
3.6 The U.S. PONV Drugs Revenue
3.6.1 The U.S. Baremsis Drug Revenue Forecast
3.7 Europe CINV Drugs Revenue
3.7.1 Europe Varuby Oral Drug Revenue Forecast
3.7.2 Europe Varuby IV Drug Revenue Forecast
4. Market Dynamics
4.1 Growth Drivers
4.1.1 Increasing Cancer Incidence
4.1.2 Growing Female Population
4.1.3 Increasing Pharmaceutical R&D Spending
4.1.4 Growing Healthcare Expenditure
4.1.5 Accelerating Economic Growth
4.2 Key Trends and Developments
4.2.1 Progressing Drugs under Pipeline
4.2.2 High Demand for Combination Therapy
4.2.3 Increasing Preference for Pressure Point Therapy
4.3 Challenges
4.3.1 Entry of Generics
4.3.2 Stringent Regulations
4.3.3 Treatment Cost
5. Competitive Landscape
5.1 Global Market
5.1.1 Revenue Comparison of Key Players
5.1.2 CINV & PONV Treatment Cost Comparison by Company
5.2 The U.S.
5.2.1 The U.S. CINV and PONV Market Share by Company
6. Company Profiles
6.1 Merck & Co., Inc.
6.1.1 Business Overview
6.1.2 Financial Overview
6.1.3 Business Strategies
6.2 Eisai Co., Ltd.
6.2.1 Business Overview
6.2.2 Financial Overview
6.2.3 Business Strategies
6.3 Kirin Holding Company, Limited (ProStrakan)
6.3.1 Business Overview
6.3.2 Financial Overview
6.3.3 Business Strategies
6.4 Helsinn Holding S.A.
6.4.1 Business Overview
6.4.2 Financial Overview
6.4.3 Business Strategies
List of Figures
- Sub-Categories of CINV
- Global CINV Market Forecast by Value (2017-2022)
- Global PONV Market Forecast by Value (2017-2022)
- The U.S. CINV & PONV Market Forecast by Value (2017-2022)
- The U.S. CINV & PONV Drugs Revenue by Categories (2017)
- The U.S. Aloxi Drug Revenue (2013-2017)
- The U.S. Aloxi Drug Revenue Forecast (2018-2022)
- The U.S. Emend Drug Revenue Forecast (2017-2022)
- The U.S. Sustol Drug Revenue Forecast (2017-2022)
- The U.S. Cinvanti Drug Revenue Forecast (2018-2022)
- The U.S. Varubi Oral Drug Revenue Forecast (2018-2022)
- The U.S. Varubi IV Drug Revenue Forecast (2018-2022)
- The U.S. PONV Patient Population Forecast (2018-2022)
- The U.S. Baremsis Drug Revenue Forecast (2019-2023)
- Europe Varuby Oral Drug Revenue Forecast (2018-2022)
- Europe Varuby IV Drug Revenue Forecast (2018-2022)
- Global Cancer New Cases (2013-2017)
- Global Female Population* (2013-2017)
- Global Pharmaceutical R&D Spending (2013-2017)
- Global Healthcare Expenditure (2013-2017)
- Global GDP Per Capita (2013-2017)
- The U.S. CINV and PONV Market Share by Company (2017)
- Merck & Co., Inc. Net Sales by Business Segments (2017)
- Merck & Co., Inc. Net Sales and Net Income (2013-2017)
- Merck & Co., Inc. Research and Development Expenditures (2015-2017)
- Eisai Co., Ltd. Revenues by Business Segments (2017*)
- Eisai Co., Ltd. Revenues and Net Profit (2013-2017*)
- Eisai Co., Ltd Research and Development Expenditures (2015-2017)
- Kirin Holding (ProStrakan) Net Sales by Business Segments (2017)
- Kirin Holding (ProStrakan) Net Sales and Net Income (Loss) (2013-2017)
- Kirin Holding Company, Limited (ProStrakan) A&P Expenditures (2015-2017)
- Helsinn Holding S.A. Net Sales (2013-2016)
- Causes of PONV
- Drugs under Development for CINV & PONV
- Generics for CINV Therapies (2016-2018)
- Key Players - Revenues Comparison (2017)
- CINV & PONV Treatment Cost Comparison by Company (2018)
- Helsinn Holding S.A. Drug Pipeline (2018)
Note: Product cover images may vary from those shown
3 of 5
LOADING...
4 of 5
- Merck & Co., Inc.
- Eisai Co., Ltd.
- Kirin Holding Company, Limited (ProStrakan)
- Helsinn Holding S.A.
Note: Product cover images may vary from those shown
5 of 5
LOADING...
